Gensci-059 is under clinical development by GeneScience Pharmaceuticals and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Gensci-059’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Gensci-059 is under development for the treatment of non-Hodgkin lymphoma, advanced malignant solid tumors, relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome. It acts by targeting CD47. It is administered through parenteral route.
GeneScience Pharmaceuticals overview
GeneScience Pharmaceuticals is a pharmaceutical company that manufactures, develops, and markets biologic therapeutics and biogenerics, among others. The company offers products such as genfulin rhGM-CSF gel and jintropin rhGH, and jintropin rhGH liquid formulations, among others. It also provides marketing of race water and satin powder injections. GeneScience Pharmaceuticals offers child growth hormone deficiencies products, endocrinology products, oncology products, burns products, surgery products, healthcare products, pharmaceutical products, and assistant reproduction products, among others. The company has its operations in Mexico, China, Hong Kong, Peru, Pakistan, Macau, Russia, and Ukraine. GeneScience Pharmaceuticals is headquartered in Changchun, China.
For a complete picture of Gensci-059’s drug-specific PTSR and LoA scores, buy the report here.